Stoke Therapeutics granted FDA orphan drug designation for STK-001 for Dravet Syndrome
Dravet syndrome is a severe and progressive genetic epilepsy, characterized by frequent, prolonged and refractory seizures beginning within the first year of life. The effects of the disease